Jan 12, 2026
How do anti‑amyloid monoclonal antibodies differ in mechanism, efficacy, and safety (lecanemab vs donanemab vs aducanumab)?
Anti‑amyloid monoclonal antibodies differ in what forms of Aβ they bind, how much they lower brain amyloid and downstream biomarkers, and in clinical benefit versus risk balance: lecanemab targets sol...